Evrysdi Insurance Denied? How to Appeal Risdiplam Coverage for SMA

Evrysdi (risdiplam) is an oral SMN2 splicing modifier approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Unlike other SMA treatments that require spinal injections or gene therapy infusions, Evrysdi is a daily oral liquid — a meaningful advantage for patients who cannot tolerate intrathecal procedures or who prefer a home-based treatment. Despite its broad approval and established safety record, insurance denials are common and can significantly delay or disrupt treatment for patients with a rapidly progressive neuromuscular disease.

If your Evrysdi claim has been denied, this guide explains the key denial arguments and how to build an effective appeal.

Why Insurers Deny Evrysdi

Age or SMA type restrictions. Insurers may attempt to limit coverage to specific SMA types (Type 1 only, for example) or age groups, even when the FDA label covers a broad population of SMA patients of all types and ages. Coverage restrictions that are narrower than the FDA label require active challenge.

Step therapy favoring another SMA drug. Because three SMA treatments now exist — nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi) — insurers may require patients to first use or fail one particular drug before approving another. This can be problematic for patients with clinical reasons to prefer Evrysdi, such as intolerance of intrathecal procedures or contraindications to gene therapy.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denial. Prior authorization is required for Evrysdi at most plans, and initial denials based on incomplete documentation or administrative reasons are common.

Medical necessity disputes. Some insurers challenge whether SMA severity meets their internal criteria for approval, requiring detailed clinical documentation.

Off-label use. While Evrysdi's FDA approval is broad, some off-label uses for related SMN1 conditions may be denied. Confirm that the indication is within the FDA-approved label before appeal.

FDA Approval Status

Evrysdi received FDA approval on August 7, 2020, for SMA in patients 2 months and older, making it the first oral SMA therapy approved. The approval was based on the FIREFISH trial (for Type 1 infantile SMA) and SUNFISH trial (for older patients with Type 2/3 SMA), both showing significant improvements in motor function. In 2021, Evrysdi's label was expanded to include presymptomatic infants.

Evrysdi holds FDA Orphan Drug Designation, Breakthrough Therapy Designation, and Priority Review. These designations reflect the FDA's determination that Evrysdi addresses a serious and life-threatening condition with compelling evidence of benefit.

Building Your Appeal

Neurologist letter of medical necessity. Your neuromuscular specialist should document the SMA type and diagnosis (with genetic confirmation of biallelic SMN1 deletion or mutation), current functional status, rate of disease progression, prior SMA treatments and their outcomes, and the clinical rationale for Evrysdi specifically (including any patient-specific reasons the oral route is preferred).

FIREFISH and SUNFISH trial data. Published results in Lancet Neurology and other peer-reviewed journals demonstrate significant functional motor improvements in treated patients across SMA types. Include key citations in your appeal.

Genetic test documentation. Include the genetic report confirming SMN1 deletion/mutation and SMN2 copy number, which are directly relevant to SMA diagnosis and treatment response.

Step therapy rebuttal. If step therapy requirements are cited, address them directly. If Evrysdi is preferred over alternative SMA treatments based on route of administration, patient age, prior treatment response, or clinical contraindications, document these reasons thoroughly.

Curetality of SMA data. The NURTURE trial demonstrated that presymptomatic treatment in infants produces near-normal motor development. While this applies to earlier identification, the broader principle that early and sustained SMA treatment significantly alters outcomes supports urgency arguments.

CureSMA and Muscular Dystrophy Association guidelines. Professional and patient advocacy organizations have published guidance on SMA treatment that can support your appeal.

Expedited Review Rights

SMA, particularly in infants and young children, is a rapidly progressive condition. SMA Type 1 is the leading genetic cause of infant mortality. If a patient is an infant or young child with Type 1 SMA, or if any patient is experiencing active functional decline, request expedited review explicitly. The treating neurologist should document that delay of even weeks risks irreversible loss of motor function or respiratory compromise.

External Independent Review: Complete Guide" class="auto-link">External Review

After internal appeal denial, external review provides an independent evaluation. For FDA-approved SMA therapies denied on restrictive criteria narrower than the label, external review has a strong track record of reversals. File for external review within the deadline specified in your denial notice.

Patient Assistance Programs

Genentech (a member of the Roche Group) manufactures Evrysdi and offers the Evrysdi patient support program with insurance navigation, co-pay assistance, and a free drug program for eligible patients. Contact their patient access team immediately upon denial.

The SMA Foundation, CureSMA (Cure Spinal Muscular Atrophy), and NORD all provide advocacy and financial resources for SMA patients. CureSMA in particular has insurance appeal resources and can connect patients with experienced advocates.

Fight Back With ClaimBack

Every day with untreated SMA means potential loss of motor neurons that cannot be recovered. An Evrysdi denial is urgent and actionable. ClaimBack helps SMA patients and families build compelling insurance appeals quickly, with the clinical and regulatory language that gets results.

Start your appeal today at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied